HIV Overview

HIV stands for human immunodeficiency virus, which is the virus that causes HIV infection. The abbreviation “HIV” can refer to the virus or to HIV infection.

AIDS stands for acquired immunodeficiency syndrome. AIDS is the most advanced stage of HIV infection.

HIV attacks and destroys the infection-fighting CD4 cells (CD4 T lymphocyte) of the immune system. The loss of CD4 cells makes it difficult for the body to fight off infections and certain cancers. Without treatment, HIV can gradually destroy the immune system and HIV infection advances to AIDS.

The spread of HIV from person to person is called HIV transmission. HIV is spread only through certain body fluids from a person who has HIV. These body fluids include:

• Blood
• Semen
• Pre-seminal fluid
• Vaginal fluids
• Rectal fluids
• Breast milk

HIV transmission is only possible through contact with HIV-infected body fluids. In the United States, HIV is spread mainly by:

• Having anal or vaginal sex with someone who has HIV without using a condom or taking medicines to prevent or treat HIV
• Sharing injection drug equipment (works), such as needles or syringes, with someone who has HIV

The spread of HIV from a woman with HIV to her child during pregnancy, childbirth, or breastfeeding is called perinatal transmission of HIV. For more information, read the HIVinfo fact sheet on Preventing Perinatal Transmission of HIV.

You cannot get HIV by shaking hands or hugging a person who has HIV. You also cannot get HIV from contact with objects, such as dishes, toilet seats, or doorknobs, used by a person with HIV. HIV is not spread through the air or water or by mosquitoes, ticks, or other blood-sucking insects. Use the HIVinfo You Can Safely Share…With Someone With HIV infographic to spread this message.

To reduce your risk of HIV infection, use condoms correctly every time you have sex, limit your number of sexual partners, and never share injection drug equipment.

Also talk to your health care provider about pre-exposure prophylaxis (PrEP). PrEP is an HIV prevention option for people who do not have HIV but who are at high risk of becoming infected with HIV. PrEP involves taking a specific HIV medicine every day. For more information, read the HIVinfo fact sheet on Pre-exposure Prophylaxis (PrEP).

HIV medicines, given to people with HIV during pregnancy and childbirth and to their babies after birth, reduce the risk of perinatal transmission of HIV. Pregnant people with HIV are encouraged to talk to their medical team about options for feeding their baby after birth. With consistent use of HIV medication and an undetectable viral load during pregnancy and throughout breastfeeding, the risk of transmission to a breastfed baby is low: less than 1%, but not zero. Alternatively, properly prepared formula and pasteurized donor human milk from a milk bank are options that eliminate the risk of transmission to a baby after birth. Pregnant people with HIV can speak with their health care provider to determine what method of feeding their baby is right for them.

Antiretroviral therapy (ART) is the use of HIV medicines to treat HIV infection. People on ART take a combination of HIV medicines (called an HIV treatment regimen) every day.

ART is recommended for everyone who has HIV. ART prevents HIV from multiplying, which reduces the amount of HIV in the body (called the viral load). Having less HIV in the body protects the immune system and prevents HIV infection from advancing to AIDS. ART cannot cure HIV, but HIV medicines help people with HIV live longer, healthier lives.

ART also reduces the risk of HIV transmission. A main goal of ART is to reduce a person’s viral load to an undetectable level. An undetectable viral load means that the level of HIV in the blood is too low to be detected by a viral load test. People with HIV who maintain an undetectable viral load have effectively no risk of transmitting HIV to their HIV-negative partner through sex.

Within 2 to 4 weeks after infection with HIV, some people may have flu-like symptoms, such as fever, chills, or rash. The symptoms may last for a few days to several weeks. Other possible symptoms of HIV include night sweats, muscle aches, sore throat, fatigue, swollen lymph nodes, and mouth ulcers. Having these symptoms do not mean you have HIV. Other illnesses can cause the same symptoms. Some people may not feel sick during early HIV infection (called acute HIV infection). During this earliest stage of HIV infection, the virus multiplies rapidly. After the initial stage of infection, HIV continues to multiply but at very low levels.

More severe symptoms of HIV infection, such as a badly damaged immune system and signs of opportunistic infections, generally do not appear for many years until HIV has advanced to AIDS. People with AIDS have badly damaged immune systems that make them prone to opportunistic infections. (Opportunistic infections are infections and infection-related cancers that occur more frequently or are more severe in people with weakened immune systems than in people with healthy immune systems.)

Without treatment with HIV medicines, HIV infection usually advances to AIDS in 10 years or longer, though it may advance faster in some people.

HIV transmission is possible at any stage of HIV infection—even if a person with HIV has no symptoms of HIV.

Symptoms such as fever, weakness, and weight loss may be a sign that a person’s HIV has advanced to AIDS. However, a diagnosis of AIDS is based on the following criteria:

• A drop in CD4 count to less than 200 cells/mm³. A CD4 count measures the number of CD4 cells in a sample of blood. 

         OR

• The presence of certain opportunistic infections.

Although an AIDS diagnosis indicates severe damage to the immune system, HIV medicines can still help people at this stage of HIV infection.

From Centers for Disease Control and Prevention:

• HIV Basics
• About HIV
• AIDS and Opportunistic Infections

From the Department of Health and Human Services (HHS):

• Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection:
  • Introduction

From the National Institute of Allergy and Infectious Diseases (NIAID):

• HIV/AIDS

Also see the HIV Source collection of HIV links and resources. For more information regarding breastfeeding and infant feeding, see HIVE and the Well Project.

HIV attacks and destroys the CD4 cells (CD4 T lymphocyte) of the immune system. CD4 cells are a type of white blood cell that play a major role in protecting the body from infection. HIV uses the machinery of the CD4 cells to multiply and spread throughout the body. This process, which is carried out in seven steps or stages, is called the HIV life cycle.

Antiretroviral therapy (ART) is the use of a combination of HIV medicines to treat HIV infection. People on ART take a combination of HIV medicines (called an HIV treatment regimen) every day. HIV medicines protect the immune system by blocking HIV at different stages of the HIV life cycle. HIV medicines are grouped into different drug classes according to how they fight HIV. Each class of drugs is designed to target a specific step in the HIV life cycle.

Because an HIV treatment regimen includes HIV medicines from at least two different HIV drug classes, ART is very effective at preventing HIV from multiplying. Having less HIV in the body protects the immune system and prevents HIV from advancing to acquired immunodeficiency syndrome (AIDS).

ART cannot cure HIV, but HIV medicines help people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV transmission (the spread of HIV to others).

The seven stages of the HIV life cycle are: 1) binding, 2) fusion, 3) reverse transcription, 4) integration, 5) replication, 6) assembly, and 7) budding.

To understand each stage in the HIV life cycle, it helps to first imagine what HIV looks like.

Now, follow each stage in the HIV life cycle as HIV attacks a CD4 cell and uses the machinery of the cell to multiply.

From the National Institute of Allergy and Infectious Diseases:

• HIV Replication Cycle
• Antiretroviral Drug Discovery and Development

Also see the HIV Source collection of HIV links and resources.

HIV Infection

Without treatment, HIV infection advances in stages, getting worse over time. HIV gradually destroys the immune system and eventually causes acquired immunodeficiency syndrome (AIDS).

There is no cure for HIV, but treatment with HIV medicines (called antiretroviral therapy or ART) can slow or prevent HIV from advancing from one stage to the next. HIV medicines help people with HIV live longer, healthier lives. One of the main goals of ART is to reduce a person's viral load to an undetectable level. An undetectable viral load means that the level of HIV in the blood is too low to be detected by a viral load test. People with HIV who maintain an undetectable viral load have effectively no risk of transmitting HIV to their HIV-negative partner through sex.

There are three stages of HIV infection:

1. Acute HIV Infection

   Acute HIV infection is the earliest stage of HIV infection, and it generally develops within 2 to 4 weeks after infection with HIV. During this time, some people have flu-like symptoms, such as fever, headache, and rash. In the acute stage of infection, HIV multiplies rapidly and spreads throughout the body. The virus attacks and destroys the infection-fighting CD4 cells (CD4 T lymphocyte) of the immune system. During the acute HIV infection stage, the level of HIV in the blood is very high, which greatly increases the risk of HIV transmission. A person may experience significant health benefits if they start ART during this stage.

2. Chronic HIV Infection

   The second stage of HIV infection is chronic HIV infection (also called asymptomatic HIV infection or clinical latency). During this stage, HIV continues to multiply in the body but at very low levels. People with chronic HIV infection may not have any HIV-related symptoms. Without ART, chronic HIV infection usually advances to AIDS in 10 years or longer, though in some people it may advance faster. People who are taking ART may be in this stage for several decades. While it is still possible to transmit HIV to others during this stage, people who take ART exactly as prescribed and maintain an undetectable viral load have effectively no risk of transmitting HIV to an HIV-negative partner through sex.

3. AIDS

   AIDS is the final, most severe stage of HIV infection. Because HIV has severely damaged the immune system, the body cannot fight off opportunistic infections. (Opportunistic infections are infections and infection-related cancers that occur more frequently or are more severe in people with weakened immune systems than in people with healthy immune systems.) People with HIV are diagnosed with AIDS if they have a CD4 count of less than 200 cells/mm3 or if they have certain opportunistic infections. Once a person is diagnosed with AIDS, they can have a high viral load and are able to transmit HIV to others very easily. Without treatment, people with AIDS typically survive about 3 years.

From HIV.gov:

• What Are HIV and AIDS?

From the Centers for Disease Control and Prevention (CDC):

• About HIV

Also see the HIV Source collection of HIV links and resources.

A latent HIV reservoir is a group of immune system cells in the body that are infected with HIV but are not actively producing new virus.

HIV attacks immune system cells in the body and uses the cells’ own machinery to make copies of itself. However, some HIV-infected immune cells go into a resting or latent state. While in this resting state, the infected cells do not produce new virus. HIV can hide inside these cells for years, forming a latent HIV reservoir but, at any time, cells in the latent reservoir can become active again and start making more virus.

To find out more about how HIV attacks cells, read the HIV Life Cycle fact sheet from HIVinfo.

HIV medicines prevent HIV from multiplying, which reduces the amount of the virus in the body (called the viral load). Because the HIV-infected cells in a latent reservoir are not producing new copies of the virus, HIV medicines have no effect on them.

People with HIV must take a daily combination of HIV medicines (called an HIV treatment regimen) to keep their viral loads low. If a person stops taking their HIV medicines, the infected cells of the latent reservoir can begin making HIV again and the person's viral load will increase. That is why it is important to continue taking HIV medicines every day as prescribed, even when viral load levels are low.

Finding ways to target and destroy latent reservoirs is a major challenge facing HIV researchers. Researchers are exploring different strategies for clearing out reservoirs, including:

• Using gene therapy (manipulating genes to treat or prevent disease) to cut out certain HIV genes and inactivate the virus in HIV-infected immune cells.
• Developing drugs or other methods to reactivate latent HIV so that the HIV can be destroyed by the immune system or new HIV therapies. This means of eliminating latent HIV reservoirs is sometimes known as the “shock and kill” or “kick and kill” strategy.

From the National Institute of Allergy and Infectious Diseases:

• HIV/AIDS Treatment
• HIV Viral Eradication
• Sustained ART-Free HIV Remission

Also see the HIV Source collection of HIV links and resources.

HIV testing determines if a person is infected with HIV. The human immunodeficiency virus (HIV) is the virus that causes acquired immunodeficiency syndrome (AIDS). AIDS is the most advanced stage of HIV infection.

HIV testing can detect HIV infection, but it cannot tell how long a person has had HIV or if the person has AIDS.

Knowing your HIV status can help keep you—and others—safe.

If you are HIV negative:

A negative HIV test result shows that you do not have HIV. Continue taking steps to avoid getting HIV, such as using condoms during sex and, if you are at high risk of getting HIV, taking medicines to prevent HIV (called pre-exposure prophylaxis or PrEP). For more information, read the HIVinfo fact sheet on The Basics of HIV Prevention.

If you are HIV positive:

A positive HIV test result shows that you have HIV, but you can still take steps to protect your health. Begin by talking to your health care provider about antiretroviral therapy (ART). People on ART take a combination of HIV medicines every day to treat HIV infection. ART is recommended for everyone who has HIV, and people with HIV should start ART as soon as possible. ART cannot cure HIV, but HIV medicines help people with HIV live longer, healthier lives.

A main goal of ART is to reduce a person’s viral load to an undetectable level. An undetectable viral load means that the level of HIV in the blood is too low to be detected by a viral load test. People with HIV who maintain an undetectable viral load have effectively no risk of transmitting HIV to their HIV-negative partner through sex.

The Centers for Disease Control and Prevention (CDC) recommends that everyone 13 to 64 years of age get tested for HIV at least once as part of routine health care. As a general rule, people at higher risk for HIV should get tested each year. Sexually active gay and bisexual men may benefit from getting tested more often, such as every 3 to 6 months. If you are over 64 years of age and at risk, your health care provider may recommend HIV testing.

Factors that increase the risk of HIV include:

• Having vaginal or anal sex with someone who is HIV positive or whose HIV status you do not know
• Injecting drugs and sharing needles, syringes, or other drug equipment with others
• Exchanging sex for money or drugs
• Having a sexually transmitted disease (STD), such as syphilis
• Having sex with anyone who has any of the HIV risk factors listed above

Talk to your health care provider about your risk for HIV and how often you should get tested for HIV.

CDC recommends that all pregnant women get tested for HIV so that they can begin taking HIV medicines if they are HIV positive. Women with HIV take HIV medicines during pregnancy and childbirth to reduce the risk of perinatal transmission of HIV and to protect their own health. For more information, read the HIVinfo fact sheet on Preventing Perinatal Transmission of HIV.

There are three types of tests used to diagnose HIV infection: antibody tests, antigen/antibody tests, and nucleic acid tests (NATs). Your health care provider can determine the appropriate HIV test for you. How soon each test can detect HIV infection differs, because each test has a different window period. The window period is the time between when a person may have been exposed to HIV and when a test can accurately detect HIV infection.

• Antibody tests check for HIV antibodies in blood or oral fluid. HIV antibodies are disease-fighting proteins that the body produces in response to HIV infection. Most rapid tests and home use tests are antibody tests.
• Antigen/antibody tests can detect both HIV antibodies and HIV antigens (a part of the virus) in the blood.
• NATs look for HIV in the blood.

A person’s initial HIV test will usually be either an antibody test or an antigen/antibody test. NATs are very expensive and not routinely used for HIV screening unless the person had a high-risk exposure or a possible exposure with early symptoms of HIV infection.

When an HIV test is positive, a follow-up test will be conducted. Sometimes people will need to visit a health care provider to take a follow-up test. Other times, the follow-up test may be performed in a lab using the same blood sample that was provided for the first test. A positive follow-up test confirms that a person has HIV.

Talk to your health care provider about your HIV risk factors and the best type of HIV test for you.

HIV testing can be confidential or anonymous. 

Confidential testing means that your HIV test results will include your name and other identifying information, and the results will be included in your medical record. HIV-positive test results will be reported to local or state health departments to be counted in statistical reports. Health departments remove all personal information (including names and addresses) from HIV test results before sharing the information with CDC. CDC uses this information for reporting purposes and does not share this information with any other organizations, including insurance companies.

Anonymous testing means you do not have to give your name when you take an HIV test. When you take the test, you receive a number. To get your HIV test results, you give the number instead of your name.

Your health care provider can give you an HIV test. HIV testing is also available at many hospitals, medical clinics, substance use programs, and community health centers. Use CDC's GetTested treatment locator to find an HIV testing location near you. Getting tested through a professional health care provider is recommended; however, there are HIV self-testing kits available. Rapid self-test and mail-in self-test are the two types of HIV self-tests, but state laws regarding self-testing may limit their availability in a location.

A rapid self-test is an oral fluid test done entirely at home or in private. There is currently one U.S. Food and Drug Administration (FDA)-approved rapid self-test called OraQuick In-Home HIV test. A mail-in self-test requires a person to provide a blood sample from a fingerstick, which is then sent to a lab for testing.

From CDC:

• Getting Tested
• HIV Basics: Testing
• HIV Testing
• Self-Testing
• Self-Testing: A Convenient and Private Option

From FDA:

• OraQuick In-Home HIV Test

Also see the HIV Source collection of HIV links and resources.

From FDA:

• HIV and AIDS: Medicines to Help You

From the National Library of Medicine:

• Drug information from the DailyMed website

Also see the HIV Source collection of HIV links and resources.

From FDA:

• HIV and AIDS: Medicines to Help You

From the National Library of Medicine:

• Drug information from the DailyMed website

Also see the HIV Source collection of HIV links and resources.

An investigational HIV drug is an experimental drug that is being studied to see whether it is safe and effective. Investigational HIV drugs are studied in medical research studies called clinical trials. Once an investigational HIV drug has been proven safe and effective in a clinical trial, the U.S. Food and Drug Administration (FDA) may approve the drug for general use or sale in the United States.

Investigational HIV drugs being studied include drugs to treat HIV and prevent HIV. Some types of investigational HIV drugs being studied include microbicides, immune modulators, latency-reversing agents, gp120 attachment inhibitors, and rev inhibitors.

HIV researchers are also studying investigational vaccines to prevent HIV and treat HIV. The goal of a preventive HIV vaccine is to prevent HIV in people who do not have HIV but who may be exposed to the virus. A safe and effective HIV treatment vaccine (also called a therapeutic HIV vaccine) could prevent HIV from advancing to acquired immunodeficiency syndrome (AIDS), replace the daily use of HIV medicines, and help prevent HIV transmission.

To learn more, read the HIVinfo What is a Preventive HIV Vaccine? and What is a Therapeutic HIV Vaccine? fact sheets.

Clinical trials are conducted in phases. Each phase has a different purpose and helps researchers answer different questions about the investigational drug.

• Phase 1 trial: Initial testing in a small group of people (20–80) to evaluate the drug’s safety and to identify side effects.
• Phase 2 trial: Testing in a larger group of people (100–300) to determine the drug’s effectiveness and to further evaluate its safety.
• Phase 3 trial: Continued testing in large groups of people (1,000–3,000) to confirm the drug’s effectiveness, monitor side effects, compare it with standard or equivalent treatments, and collect information to ensure that the investigational drug can be used safely.
  
  In most cases, an investigational drug must be proven effective and must show continued safety in a Phase 3 clinical trial to be considered for approval by the FDA for sale in the United States. (However, some drugs go through the FDA’s accelerated approval process and are approved before a Phase 3 clinical trial is complete.)
• Phase 4 trial: Ongoing tracking that occurs after a drug is approved by the FDA for sale in the United States. The purpose of the tracking is to seek more information about the drug’s risks, benefits, and optimal use.

For more information, read the HIVinfo HIV and AIDS Clinical Trials fact sheet.

To find an HIV and AIDS clinical trial that is studying an investigational HIV drug, use the find a study search feature on ClinicalTrials.gov.

For help with your search, call a Clinicalinfo health information specialist at 1-800-448-0440 or email ContactUs@HIVinfo.NIH.gov.

You can also join ResearchMatch, which is a free, secure online tool that makes it easier for the public to become involved in clinical trials.

In some cases, an investigational HIV drug may be available through an expanded access program. Expanded access allows for the use of an investigational drug outside of a clinical trial to treat a person who has a serious or immediate life-threatening disease and who has no FDA-approved treatment options. Drug companies must have permission from the FDA to make an investigational drug available for expanded access.

People seeking expanded access to an investigational HIV drug should talk to their health care provider to see if they may qualify to take part in an expanded access program.

One goal of HIV research is to identify safer, more effective HIV medicines. Researchers try to make clinical trials as safe as possible. However, taking an investigational HIV drug can involve both benefits and risks. Risks may include unexpected side effects from the drug, which can be unpleasant, serious, or even life-threatening.

The benefits and possible risks of participating in a clinical trial or an expanded access program are explained to people before they decide whether to participate.

To find more information on investigational HIV drugs, use the Clinicalinfo Drug Database, which includes up-to-date information on many investigational HIV drugs.

From the National Institutes of Health (NIH):

• NIH Clinical Research Trials and You: The Basics
• NIH Clinical Research Trials and You: Finding a Clinical Trial

From the National Institute of Allergy and Infectious Diseases:

• HIV/AIDS

From the U.S. Food and Drug Administration (FDA):

• Expanded Access | Information for Patients

Also see the HIV Source collection of HIV links and resources.

A therapeutic HIV vaccine is a vaccine that is designed to improve the body’s immune response to HIV in a person who already has HIV.

Researchers are developing and testing therapeutic HIV vaccines to slow down the progression of HIV to acquired immunodeficiency syndrome (AIDS). The hope is that treating people with these vaccines would ideally keep HIV at undetectable levels (known as undetectable viral load) without the need for regular antiretroviral therapy (ART). ART is the recommended treatment for HIV infection and involves using a combination of different HIV medicines to prevent HIV from multiplying. Currently, a person with HIV must remain on ART to keep HIV at undetectable levels.

A therapeutic HIV vaccine may also make it less likely that a person could transmit HIV to others.

There are currently no U.S. Food and Drug Administration (FDA)-approved therapeutic HIV vaccines, but research is underway. You must be enrolled in a clinical trial to receive a therapeutic HIV vaccine.

A preventive HIV vaccine is given to people who do not have HIV, with the goal of preventing HIV infection in the future. The vaccine teaches the person's immune system to recognize and effectively fight HIV in case the virus ever enters the person’s body. To learn more, read the HIVinfo What is a Preventive HIV Vaccine? fact sheet.

A therapeutic HIV vaccine is given to people who already have HIV. The goal of a therapeutic HIV vaccine is to strengthen a person’s immune response to the HIV that is already in the person's body.

A list of clinical trials on therapeutic HIV vaccines is available from the database of ClinicalTrials.gov study summaries. Click on the title of any trial in the list to see more information about the study.

If you are interested in participating in a vaccine study, you can also contact the National Institutes of Health Vaccine Research Center by calling 866-833-LIFE (5433) or by emailing vaccines@nih.gov. To learn more, read the HIVinfo fact sheet on HIV and AIDS Clinical Trials.

From the National Institute of Allergy and Infectious Diseases:

• HIV Vaccine Development
• Sustained ART-Free HIV Remission

From the HIV Vaccine Trials Network:

• How Vaccines Work

Also see the HIV Source collection of HIV links and resources.

A preventive HIV vaccine is given to people who do not have HIV, with the goal of preventing HIV infection in the future. The vaccine teaches the person's immune system to recognize and effectively fight HIV in case the person is ever exposed to HIV.

Currently, no preventive HIV vaccines have been approved by the U.S. Food and Drug Administration (FDA), but research is underway. You must be enrolled in a clinical trial to receive a preventive HIV vaccine.

While a preventive HIV vaccine is given to people who do not have HIV, a therapeutic HIV vaccine is given to people who already have HIV. The goal of a therapeutic HIV vaccine is to strengthen a person’s immune response to the HIV that is already in the person’s body. Researchers are exploring the use of therapeutic HIV vaccines:

• To slow down the progression of HIV infection
• To eliminate the need for antiretroviral therapy (ART) while keeping undetectable levels of HIV

To learn more, read the HIVinfo What is a Therapeutic HIV Vaccine? fact sheet.

No, a person cannot get HIV from a preventive HIV vaccine. The preventive HIV vaccines being studied in clinical trials do not contain HIV. Of the approximately 30,000 people who have participated in HIV vaccine studies around the world in the last 25 years, no one has gotten HIV from any of the vaccines tested.

Treatment options for HIV have improved a lot over the last 30 years. But HIV medicines can have side effects, can be expensive, and can be hard to access in some countries. Also, some people may develop drug resistance to certain HIV medicines and then must change medicines.

Using condoms correctly and taking pre-exposure prophylaxis (PrEP) can help prevent HIV transmission. But researchers believe a preventive HIV vaccine will be the most effective way to completely end new HIV infections.

Some of the areas of interest being studied in clinical trials include:

• The safety of preventive vaccines.
• Whether a preventive vaccine protects against HIV infection.
• Whether a preventive vaccine controls HIV if a person gets HIV while enrolled in a study. (It is possible for someone to get HIV through sexual contact or from sharing drug injection equipment while they are participating in a clinical trial. But a person cannot get HIV from the HIV vaccine being tested.)
• The immune responses that occur in people who receive a preventive vaccine.
• Different ways of giving preventive vaccines, such as using a needle and syringe versus a needle-free device.

A list of clinical trials on preventive HIV vaccines is available from the database of ClinicalTrials.gov study summaries. Click on the title of any trial in the list to see more information about the study.

If you are interested in participating in a vaccine study, you can also contact the National Institutes of Health Vaccine Research Center by calling 866-833-LIFE (5433) or by emailing vaccines@nih.gov.

To learn more, read the HIVinfo fact sheet on HIV and AIDS Clinical Trials.

From the National Institute of Allergy and Infectious Diseases:

• HIV Vaccine Development

From the HIV Vaccine Trials Network (HVTN):

• How Vaccines Work
• HIV Vaccine Myths and Facts
• HVTN Trials

Also see the HIV Source collection of HIV links and resources.

A clinical trial is a research study that evaluates new medical approaches in people. These approaches include:

• new medicines or new combinations of medicines
• new medical devices or surgical procedures
• new ways to use an existing medicine or device
• new ways to change behaviors to improve health

Clinical trials are conducted in several phases to determine whether new medical approaches are safe and effective in people. Results from a Phase 1 Trial, Phase 2 Trial, and Phase 3 Trial are used to determine whether a new drug should be approved for sale in the United States. Once a new drug is approved, researchers continue to track its safety in a Phase 4 Trial.

Interventional trial and observational trial are two main types of clinical trials.

HIV and AIDS clinical trials help researchers find better ways to prevent, detect, or treat HIV and AIDS. Every HIV medicine was first studied through clinical trials.

Examples of HIV and AIDS clinical trials include:

• studies of new medicines to prevent or treat HIV and AIDS
• studies of vaccines to prevent or treat HIV
• studies of medicines to treat infections related to HIV and AIDS

It depends on the study. Some HIV and AIDS clinical trials enroll only people who have HIV. Other studies include people who do not have HIV.

Participation in an HIV and AIDS clinical trial may also depend on other factors, such as age, gender, HIV treatment history, or other medical conditions.

Participating in an HIV and AIDS clinical trial can provide benefits. For example, many people participate in HIV and AIDS clinical trials, because they want to contribute to HIV and AIDS research. They may have HIV or know someone who has HIV.

People with HIV who participate in an HIV and AIDS clinical trial may benefit from new HIV medicines before they are widely available. HIV medicines being studied in clinical trials are called investigational drugs. To learn more, read the HIVinfo What is an Investigational HIV Drug? fact sheet.

Participants in clinical trials can receive regular and careful medical care from a research team that includes doctors and other health professionals. Often the medicines and medical care are free of charge.

Sometimes people get paid for participating in a clinical trial. For example, they may receive money or a gift card. They may be reimbursed for the cost of meals or transportation.

Researchers try to make HIV and AIDS clinical trials as safe as possible. However, volunteering to participate in a study testing an experimental treatment for HIV can involve risks of varying degrees. Most volunteers do not experience serious side effects; however, potential side effects that may be serious or even life-threatening can occur from the treatment being studied.

Before enrolling in a clinical trial, potential volunteers learn about the study in a process called informed consent. The process includes an explanation of the possible risks and benefits of participating in the study.

Once enrolled in a study, people continue to receive information about the study through the informed consent process.

The privacy of study volunteers is important to everyone involved in an HIV and AIDS clinical trial. The informed consent process includes an explanation of how a study volunteer’s personal information is protected.

There are several ways to find an HIV and AIDS clinical trial looking for volunteer participants.

• Use the find a study search feature on ClinicalTrials.gov to find HIV and AIDS studies looking for volunteer participants.
• Call a Clinical  Info health information specialist at 1-800-448-0440 or email ContactUs@HIVinfo.NIH.gov.
• Join ResearchMatch, which is a free, secure online tool that makes it easier for the public to become involved in clinical trials.

From the National Institutes of Health (NIH):

• NIH Clinical Research Trials and You: The Basics

From the National Library of Medicine:

• Learn About Clinical Studies

Also see the HIV Source collection of HIV links and resources.